<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03547167</url>
  </required_header>
  <id_info>
    <org_study_id>V114-017</org_study_id>
    <secondary_id>2017-004915-38</secondary_id>
    <secondary_id>V114-017</secondary_id>
    <nct_id>NCT03547167</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to 1) describe the safety, tolerability, and immunogenicity of V114
      and Prevnar 13™ in pneumococcal vaccine-naïve adults at increased risk for pneumococcal
      disease and to 2) describe the safety, tolerability, and immunogenicity of PNEUMOVAX™23 when
      administered 6 months after receipt of either V114 or Prevnar 13™. Increased risk for
      pneumococcal disease is defined as 1) an underlying medical condition, 2) behavioral habits
      such as smoking, or 3) living in a community/environment with increased risk of disease
      transmission.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 16, 2018</start_date>
  <completion_date type="Actual">January 20, 2020</completion_date>
  <primary_completion_date type="Actual">January 20, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with a Solicited Injection-site Adverse Event</measure>
    <time_frame>Up to Day 5 after Vaccination 1</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited injection-site AEs will be redness/erythema, swelling, and pain/tenderness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with a Solicited Systemic Adverse Event</measure>
    <time_frame>Up to Day 14 after Vaccination 1</time_frame>
    <description>An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs will be muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with a Vaccine-related Serious Adverse Event</measure>
    <time_frame>Up to Month 6 (before Vaccination 2)</time_frame>
    <description>A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine will be determined by the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) of Serotype-specific Opsonophagocytic Activity (OPA)</measure>
    <time_frame>Day 30</time_frame>
    <description>Activity for the 15 serotypes contained in V114 vaccine will be determined using a Multiplex Opsonophagocytic Assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with a Solicited Injection-site Adverse Event</measure>
    <time_frame>Up to Day 5 after Vaccination 2 (Month 6)</time_frame>
    <description>An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited injection-site AEs will be redness/erythema, swelling, and pain/tenderness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with a Solicited Systemic Adverse Event</measure>
    <time_frame>Up to Day 14 after Vaccination 2 (Month 6)</time_frame>
    <description>An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs will be muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with a Vaccine-related Serious Adverse Event</measure>
    <time_frame>From Month 6 (before Vaccination 2) to Month 7</time_frame>
    <description>An SAE is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine will be determined by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration of Serotype-specific Immunoglobulin G (IgG)</measure>
    <time_frame>Day 30</time_frame>
    <description>Immunoglobulin G for the 15 serotypes contained in V114 vaccine will be determined using an electrochemiluminescence assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) in Serotype-specific OPA</measure>
    <time_frame>Day 1 (Baseline) and Day 30</time_frame>
    <description>Activity for the 15 serotypes contained in V114 vaccine will be determined using a Multiplex Opsonophagocytic Assay. GMFR is GMT at Day 30 / GMT at Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR in Serotype-specific IgG</measure>
    <time_frame>Day 1 (Baseline) and Day 30</time_frame>
    <description>Immunoglobulin G for the 15 serotypes contained in V114 vaccine will be determined using an electrochemiluminescence assay. GMFR is GMC at Day 30 / GMC at Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with GMFR ≥4 in Serotype-specific OPA</measure>
    <time_frame>Day 1 (Baseline) and Day 30</time_frame>
    <description>Activity for the 15 serotypes contained in V114 vaccine will be determined using a Multiplex Opsonophagocytic Assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with GMFR ≥4 in Serotype-specific IgG</measure>
    <time_frame>Day 1 (Baseline) and Day 30</time_frame>
    <description>Immunoglobulin G for the 15 serotypes contained in V114 vaccine will be determined using an electrochemiluminescence assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer of Serotype-specific Opsonophagocytic Activity</measure>
    <time_frame>Month 7</time_frame>
    <description>Activity for the 15 serotypes contained in V114 vaccine will be determined using a Multiplex Opsonophagocytic Assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG)</measure>
    <time_frame>Month 7</time_frame>
    <description>Immunoglobulin G for the 15 serotypes contained in V114 vaccine will be determined using an electrochemiluminescence assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR in Serotype-specific OPA</measure>
    <time_frame>Day 1 (Baseline) and Month 7</time_frame>
    <description>Activity for the 15 serotypes contained in V114 vaccine will be determined using a Multiplex Opsonophagocytic Assay. GMFR is GMT at Month 7 / GMT at Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR in Serotype-specific IgG</measure>
    <time_frame>Day 1 (Baseline) and Month 7</time_frame>
    <description>Immunoglobulin G for the 15 serotypes contained in V114 vaccine will be determined using an electrochemiluminescence assay. GMFR is GMC at Month 7 / GMC at Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with GMFR ≥4 in Serotype-specific OPA</measure>
    <time_frame>Day 1 (Baseline) and Month 7</time_frame>
    <description>Activity for the 15 serotypes contained in V114 vaccine will be determined using a Multiplex Opsonophagocytic Assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with GMFR ≥4 in Serotype-specific IgG</measure>
    <time_frame>Day 1 (Baseline) and Month 7</time_frame>
    <description>Immunoglobulin G for the 15 serotypes contained in V114 vaccine will be determined using an electrochemiluminescence assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR in Serotype-specific OPA</measure>
    <time_frame>Month 6 (Baseline before Vaccination 2) and Month 7</time_frame>
    <description>Activity for the 15 serotypes contained in V114 vaccine will be determined using a Multiplex Opsonophagocytic Assay. GMFR is GMT at Month 7 / GMT at Month 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR in Serotype-specific IgG</measure>
    <time_frame>Month 6 (Baseline before Vaccination 2) and Month 7</time_frame>
    <description>Immunoglobulin G for the 15 serotypes contained in V114 vaccine will be determined using an electrochemiluminescence assay. GMFR is GMC at Month 7 / GMC at Month 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with GMFR ≥4 in Serotype-specific OPA</measure>
    <time_frame>Month 6 (Baseline before Vaccination 2) and Month 7</time_frame>
    <description>Activity for the 15 serotypes contained in V114 vaccine will be determined using a Multiplex Opsonophagocytic Assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with GMFR ≥4 in Serotype-specific IgG</measure>
    <time_frame>Month 6 (Baseline before Vaccination 2) and Month 7</time_frame>
    <description>Immunoglobulin G for the 15 serotypes contained in V114 vaccine will be determined using an electrochemiluminescence assay.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1515</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>V114</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevnar 13™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V114</intervention_name>
    <description>15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose</description>
    <arm_group_label>V114</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevnar 13™</intervention_name>
    <description>13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg), and aluminum phosphate adjuvant (125 mcg aluminum) in each 0.5 ml dose</description>
    <arm_group_label>Prevnar 13™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PNEUMOVAX™23</intervention_name>
    <description>23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose</description>
    <arm_group_label>Prevnar 13™</arm_group_label>
    <arm_group_label>V114</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Native American participant enrolled from any of the clinical sites
        of the Johns Hopkins Center for American Indian Health (CAIH) without any of the
        pre-specified risk conditions for pneumococcal disease listed below, OR Native American
        participant enrolled from any of the CAIH sites or participant from a site other than CAIH
        with ≥1 of the following risk conditions for pneumococcal disease:

          1. diabetes mellitus Type 1 or Type 2 and with hemoglobin A1c (HgA1c) &lt;10%

          2. chronic liver disease with documented history of compensated cirrhosis (Child-Pugh
             Score A)

          3. confirmed diagnosis of chronic obstructive pulmonary disease with spirometric Global
             Initiative for Chronic Obstructive Lung Disease Stage 1 to 3

          4. confirmed diagnosis of mild or moderate persistent asthma receiving guideline directed
             therapy

          5. confirmed diagnosis of chronic heart disease (New York Heart Association [NYHA] heart
             failure Class 1 to 3, receiving guideline-directed oral heart failure treatment) due
             to reduced or preserved ejection fraction or due to non-cyanotic congenital heart
             disease.

          6. current smoker - Female participant: not pregnant, not breastfeeding and 1) not of
             childbearing potential, or 2) of childbearing potential and agrees to practice
             contraception through 6 weeks after last administration of study vaccine.

        Exclusion Criteria: - History of active hepatitis within the prior 3 months - History of
        diabetic ketoacidosis, or &gt;1 episodes of severe, symptomatic hypoglycemia within the prior
        3 months - Myocardial infarction, acute coronary syndrome, transient ischemic attack, and
        ischemic or hemorrhagic stroke within the prior 3 months - History of severe pulmonary
        hypertension or history of Eisenmenger syndrome - History of invasive pneumococcal disease
        or known history of other culture-positive pneumococcal disease within the prior 3 years -
        Known hypersensitivity to any vaccine component, pneumococcal conjugate vaccine, or
        diphtheria toxoid-containing vaccine - Known or suspected impairment of immunological
        function (including human immunodeficiency virus (HIV) infection or autoimmune disease) -
        History of malignancy within the prior 5 years, except for adequately treated basal cell or
        squamous cell skin cancer or in situ cervical cancer - History of Stage 4 or 5 Chronic
        Kidney Disease or nephrotic syndrome - History of alcohol withdrawal or alcohol withdrawal
        seizure within the prior 12 months - History of coagulation disorder contraindicating
        intramuscular vaccination - History of hospitalization within the prior 3 months - Female
        participant: positive urine or serum pregnancy test - Prior administration of any
        pneumococcal vaccine - Received systemic corticosteroids (prednisone equivalent of ≥20
        mg/day) for ≥14 consecutive days and has not completed within the prior 30 days - Received
        systemic corticosteroids exceeding physiologic replacement within 14 days before study
        vaccination - Receiving immunosuppressive or immunomodulatory therapy with a biological
        agent - Received any licensed, non-live vaccine within 14 days before receipt of study
        vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following
        receipt of study vaccine - Received any live vaccine within 30 days before receipt of any
        study vaccine or is scheduled to receive any live vaccine within 30 days following receipt
        of any study vaccine - Received a blood transfusion or blood products within the prior 6
        months - Receiving chronic home oxygen therapy - Participated in another clinical study of
        an investigational product within the prior 2 months - Current user of recreational or
        illicit drugs or history of drug abuse or dependence - Diabetes mellitus with HgA1c ≥10% -
        Chronic liver disease with Child-Pugh Class B or C cirrhosis - Chronic lung disease with
        Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage 4 or severe persistent asthma -
        Chronic heart disease with NYHA heart failure Class 4.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinle Comprehensive Health Care Facility ( Site 0001)</name>
      <address>
        <city>Chinle</city>
        <state>Arizona</state>
        <zip>86503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Defiance Center for American Indian Health ( Site 0002)</name>
      <address>
        <city>Fort Defiance</city>
        <state>Arizona</state>
        <zip>86504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associates, PA ( Site 0043)</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Phoenix Medical Clinic, LLC ( Site 0031)</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whiteriver Center for American Indian Health ( Site 0005)</name>
      <address>
        <city>Whiteriver</city>
        <state>Arizona</state>
        <zip>85941</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Empire Clinical Trials, LLC ( Site 0052)</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Top Medical Research, Inc ( Site 0033)</name>
      <address>
        <city>Cutler Bay</city>
        <state>Florida</state>
        <zip>33189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indago Research &amp; Health Center, Inc ( Site 0054)</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research ( Site 0008)</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Triple O Research Institute, P.A. ( Site 0026)</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine at Grady Hospital ( Site 0027)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kootenai Health ( Site 0042)</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston Premier Healthcare &amp; Research, LLC. ( Site 0012)</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmakon Inc ( Site 0049)</name>
      <address>
        <city>Evergreen Park</city>
        <state>Illinois</state>
        <zip>60805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reid Physician Associates ( Site 0055)</name>
      <address>
        <city>Richmond</city>
        <state>Indiana</state>
        <zip>47374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Pharmaceutical Research PC ( Site 0050)</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consortium ( Site 0053)</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Associates [Bridgeton, NJ] ( Site 0015)</name>
      <address>
        <city>Bridgeton</city>
        <state>New Jersey</state>
        <zip>08302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gallup Center for American Indian Health ( Site 0003)</name>
      <address>
        <city>Gallup</city>
        <state>New Mexico</state>
        <zip>87301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shiprock Center for American Indian Health ( Site 0004)</name>
      <address>
        <city>Shiprock</city>
        <state>New Mexico</state>
        <zip>87420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corning Center For Clinical Research ( Site 0036)</name>
      <address>
        <city>Corning</city>
        <state>New York</state>
        <zip>14830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Hudson Medical Research ( Site 0022)</name>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <zip>12553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates, LLC ( Site 0016)</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Health Network ( Site 0040)</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania ( Site 0030)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain View Clinical Research ( Site 0007)</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group ( Site 0025)</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIM Trials ( Site 0060)</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch at Galveston ( Site 0034)</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-1115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice Leadership, LLC ( Site 0051)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Center For Drug Development ( Site 0041)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Institute Of Cardiology ( Site 0048)</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Village Health Partners ( Site 0006)</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Copperview Medical Center ( Site 0038)</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Timber Lane Allergy &amp; Asthma Research, LLC ( Site 0044)</name>
      <address>
        <city>South Burlington</city>
        <state>Vermont</state>
        <zip>05403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary &amp; Sleep Research ( Site 0046)</name>
      <address>
        <city>Spokane Valley</city>
        <state>Washington</state>
        <zip>99216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gundersen Health System ( Site 0021)</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic ( Site 0013)</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paratus Clinical Pty Ltd - Blacktown Clinic ( Site 0174)</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holdsworth House Medical Practice ( Site 0170)</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Core Research Group Pty limited ( Site 0175)</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4064</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emeritus Research Pty Ltd ( Site 0173)</name>
      <address>
        <city>Camberwell</city>
        <state>Victoria</state>
        <zip>3124</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paratus Clinical Kanwal ( Site 0172)</name>
      <address>
        <city>Kanwal</city>
        <zip>2259</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nepean Hospital ( Site 0176)</name>
      <address>
        <city>Kingswood</city>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Liver and Intestinal Research Centre (LAIR) ( Site 0302)</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1H2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GA Research Associates, Ltd/Ltee ( Site 0303)</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1G 1A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colchester Research Group ( Site 0094)</name>
      <address>
        <city>Truro</city>
        <state>Nova Scotia</state>
        <zip>B2N 1L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Medical Research Group ( Site 0092)</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8M 1K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SKDS Research Inc. ( Site 0099)</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omnispec Recherche Clinique Inc ( Site 0093)</name>
      <address>
        <city>Mirabel</city>
        <state>Quebec</state>
        <zip>J7J 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dynamik Research ( Site 0095)</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <zip>H9R 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Q &amp; T Research Sherbrooke Inc. ( Site 0097)</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1J 2G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diex Recherche Quebec Inc ( Site 0091)</name>
      <address>
        <city>Quebec</city>
        <zip>G1N 4V3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Arauco Salud ( Site 0100)</name>
      <address>
        <city>Santiago</city>
        <state>RM</state>
        <zip>7560994</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Clinica UC CICUC ( Site 0104)</name>
      <address>
        <city>Santiago</city>
        <zip>8330034</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CECIM ( Site 0101)</name>
      <address>
        <city>Santiago</city>
        <zip>8330336</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CESFAM Esmeralda ( Site 0102)</name>
      <address>
        <city>Santiago</city>
        <zip>9351603</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Hernan Henriquez Aravena ( Site 0105)</name>
      <address>
        <city>Temuco</city>
        <zip>4781151</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Clinical Trials - Waitemata ( Site 0183)</name>
      <address>
        <city>Auckland</city>
        <zip>0626</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies Limited ( Site 0189)</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Clinical Trials ( Site 0182)</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Heart Institute ( Site 0280)</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Clinical Trials Ltd ( Site 0180)</name>
      <address>
        <city>Christchurch</city>
        <zip>8013</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeland Clinical Trials ( Site 0181)</name>
      <address>
        <city>Rotorua</city>
        <zip>3010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay of Plenty Clinical School ( Site 0186)</name>
      <address>
        <city>Tauranga</city>
        <zip>3143</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P3 Research Ltd - Wellington ( Site 0184)</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WSOZ im.T.Browicza w Bydgoszczy ( Site 0317)</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-030</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Bydgoszcz ( Site 0139)</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. z o.o. ( Site 0238)</name>
      <address>
        <city>Gdansk</city>
        <zip>80-382</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny osrodek .All-Med. Grazyna Pulka ( Site 0233)</name>
      <address>
        <city>Krakow</city>
        <zip>30-033</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ID Clinic ( Site 0235)</name>
      <address>
        <city>Myslowice</city>
        <zip>41-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Ogrodowa Sp. Z o.o. ( Site 0319)</name>
      <address>
        <city>Skierniewice</city>
        <zip>96-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej ( Site 0314)</name>
      <address>
        <city>Sopot</city>
        <zip>81-717</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wroclawskie Centrum Zdrowia SP ZOZ ( Site 0236)</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-136</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. z o.o. oddział we Wrocławiu ( Site 0234)</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-381</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Hospital of Infectious Diseases n. a. A.F.Agafonov ( Site 0249)</name>
      <address>
        <city>Kazan</city>
        <zip>420140</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saratov State Medical University n.a. V.I.Razumovskiy ( Site 0144)</name>
      <address>
        <city>Saratov</city>
        <zip>410054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smolensk State Medical University ( Site 0246)</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 24, 2018</study_first_submitted>
  <study_first_submitted_qc>May 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2018</study_first_posted>
  <last_update_submitted>January 23, 2020</last_update_submitted>
  <last_update_submitted_qc>January 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

